Corticosteroid rescue in late paediatric acute respiratory distress syndrome

A Y Goh1, D Sekaran, M Roziah

  • 1Paediatric Intensive Care Unit, University Malaya Medical Centre, Kuala Lumpur, Malaysia. adrian@medicine.med.um.edu.my

Respirology (Carlton, Vic.)
|September 18, 1999
PubMed

Insights

This case study shows prolonged high-dose steroid treatment may improve outcomes for children with late acute respiratory distress syndrome (ARDS). Further research is needed to confirm safety and efficacy in pediatric patients.

Area of Science:

  • Pediatric Critical Care Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Late acute respiratory distress syndrome (ARDS) carries a high mortality rate, exceeding 80%.
  • Adult studies suggest prolonged steroid therapy improves survival in late ARDS, but pediatric data are limited.
  • Refractory late ARDS in children presents a significant clinical challenge with few effective treatment options.

Observation:

  • A case report details the successful treatment of a child with refractory late ARDS.
  • The child had been on advanced mechanical ventilation for 12 days prior to treatment.
  • High-dose methylprednisolone was administered for a prolonged duration.

Findings:

  • Significant clinical improvement was observed within 14 days of steroid initiation.
  • Improvements noted in oxygenation (PaO2/FiO2 ratios), lung injury scores, and chest radiography.
  • A fungal urinary tract infection was managed successfully; no major metabolic side effects occurred.

Implications:

  • Prolonged steroid therapy may be a viable option for refractory pediatric late ARDS.
  • Further prospective studies are essential to establish optimal indications, timing, dosage, and safety profiles for children.
  • This case highlights a potential therapeutic avenue for a critically ill pediatric population.

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...